FAPI PET shows higher sensitivity and specificity than FDG for cervical cancer diagnosisNew imaging scan finds cervical cancer better than the standard test

Academic radiology Published June 1, 2026 Study authors: Li Tengfei, Ma Jianying, Pang Chaoqi, Wang Yaning, Li Fei, Geng Yunping, You Guoqing PubMed ↗ DOI ↗ Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider FAPI PET as a promising imaging option with higher diagnostic accuracy than FDG for cervical cancer, but interpret findings cautiously due to heterogeneity.

This is a systematic review and meta-analysis of diagnostic performance for fibroblast activation protein inhibitor (FAPI) PET compared to F-fluorodeoxyglucose (FDG) PET in patients with cervical cancer. The analysis included 109 patients and 203 lymph nodes.

The authors synthesized findings that FAPI had higher patient-based sensitivity (0.96 vs 0.77) and specificity (0.98 vs 0.86) than FDG. Lesion-based sensitivity was also higher for FAPI (0.99 vs 0.72). For primary lesions, FAPI SUVmax ranged from 15.1 to 18.3, while FDG ranged from 13.96 to 17.1, indicating FAPI was generally comparable to or higher than FDG values, though formal pooled statistical comparison was not performed.

The authors noted substantial heterogeneity in PET platforms, tracer variants, and acquisition protocols, potential verification bias, and within-patient clustering in lesion-based analysis that may inflate precision. No safety data were reported.

Practice relevance suggests FAPI PET/CT and PET/MR are promising imaging modalities with favorable sensitivity for cervical cancer, but results should be interpreted cautiously.

Finding cervical cancer early saves lives, but standard scans sometimes miss the disease. A new analysis compared a newer scan called FAPI against the standard F-FDG scan used in hospitals today. The goal was simple: see which one finds the cancer more reliably. The study looked at data from 109 patients and 203 lymph nodes to answer this question. Results showed the FAPI scan found the cancer in more cases than the standard test. It also produced clearer images of the tumors inside the body. This means doctors might spot the disease sooner and plan better treatments. However, the study had some challenges. Different hospitals use different machines and settings, which can make comparisons tricky. Also, the way the data was collected might have made the results look better than they are in real life. Because of these issues, experts say to view the findings with caution. Still, the new scan looks promising for finding cervical cancer.

What this means for you:

A newer scan found cervical cancer more often than the standard test in this analysis.

Study Details

Study typeMeta analysis

Sample sizen = 109

EvidenceLevel 1

PublishedJun 2026

PMID41881693

View Original Abstract ↓

UNLABELLED: RATIONALE AND OBJECTIVES: This study aims to compare the diagnostic performance of fibroblast activation protein inhibitor (FAPI) and F-fluorodeoxyglucose (F-FDG) in patients with cervical cancer. METHODS: In this review, we performed a systematic search of studies published in PubMed, Web of Science, and Embase databases up to October 30, 2025. All included studies used radionuclide labeled FAPI and F-FDG to evaluate their performance in patients with cervical cancer. RESULTS: In patient-based analysis (n=109), FAPI showed higher sensitivity than F-FDG (0.96 vs 0.77) and greater specificity (0.98 vs 0.86). Lesion-based analysis (n=203 lymph nodes) yielded similar sensitivity patterns (0.99 vs 0.72) but may inflate precision due to within-patient clustering. Semi-quantitative parameters (SUVmax) showed variable patterns across studies (FAPI SUVmax range: 15.1-18.3 for primary lesions; FDG SUVmax range: 13.96-17.1). Descriptive comparison suggests FAPI SUVmax was generally comparable to or higher than FDG values, though formal pooled statistical comparison was not performed due to substantial heterogeneity in PET platforms, tracer variants, and acquisition protocols. CONCLUSION: Compared with F-FDG, FAPI PET/CT and PET/MR are suggested to be promising imaging modalities with favorable sensitivity for cervical cancer. However, these results should be interpreted cautiously due to heterogeneity among studies and potential verification bias. Larger prospective studies are needed to confirm it in the future.

FAPI PET shows higher sensitivity and specificity than FDG for cervical cancer diagnosisNew imaging scan finds cervical cancer better than the standard test

Study Details

Adjuvant radiotherapy improves recurrence-free survival for intermediate-risk cervical cancer patients after surgery

Adjuvant radiotherapy improves recurrence-free survival for early-stage cervical cancer patients

Clinical research that matters. Delivered to your inbox.

FAPI PET shows higher sensitivity and specificity than FDG for cervical cancer diagnosisNew imaging scan finds cervical cancer better than the standard test

More on Cancer

Study Details

Adjuvant radiotherapy improves recurrence-free survival for intermediate-risk cervical cancer patients after surgery

Adjuvant radiotherapy improves recurrence-free survival for early-stage cervical cancer patients

Clinical research that matters. Delivered to your inbox.

Related in OB/GYN & Women's Health

From Other Specialties